NCT07483554 2026-03-19
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Not yet recruiting
Clinical Trials
17 trialsNCT07432594 2026-02-25
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07403435 2026-02-11
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07346807 2026-01-16
Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06177522 2025-11-18
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
Jinling Hospital, China
Phase 2 Not yet recruiting
NCT07046221 2025-07-20
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT07019181 2025-06-13
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Not yet recruiting
NCT05562297 2025-01-22
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06747169 2024-12-27
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study
Second Affiliated Hospital of Zunyi Medical University
Phase 2 Not yet recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT06599775 2024-09-19
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06475755 2024-06-26
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT06404463 2024-05-08
QUEEN-Neo
Fudan University
Phase 2 Not yet recruiting
NCT06404736 2024-05-08
QUEEN-Dream
Fudan University
Phase 2 Not yet recruiting
NCT06222944 2024-01-25
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Peking University
Phase 2 Not yet recruiting
NCT06028633 2023-09-13
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Peking University First Hospital
Phase 2 Not yet recruiting
NCT04153734 2019-11-06
Evolution
Kobe Minimally Invasive Cancer Center
Phase 2 Not yet recruiting